title: Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes.
abstract: This report describes a detailed analysis how donor-specific HLA class II epitope mismatching affects antibody reactivity patterns in 75 solid organ transplant recipients with an in situ allograft and who were considered for retransplantation. Sera were tested for antibodies in a sensitive antigen-binding assay (Luminex) with single class II alleles. Their reactivity was analyzed with HLAMatchmaker, a structural matching algorithm that considers so-called eplets to define epitopes recognized by antibodies. Only 24% of the patients showed donor-specific anti-DRB1 antibodies and there was a significant correlation with a low number of mismatched DRB1 eplets. This low detection rate of anti-DRB1 antibodies may also be due to allograft absorption. In contrast, antibodies to DRB3/4/5 mismatches were more common. Especially, 83% of the DRB4 (DR53) mismatches resulted in detectable antibodies against an eplet uniquely found on DR53 antigens. Donor-specific DQB mismatches led to detectable anti-DQB antibodies with a frequency of 87%. Their specificity correlated with eplets uniquely found on DQ1-4. The incidence of antibodies induced by 2-digit DQA mismatches was 64% and several eplets appeared to play a dominant role. These findings suggest that both alpha and beta chains of HLA-DQ heterodimers have immunogenic epitopes that can elicit specific antibodies. About one-third of the sera had anti-DP antibodies; they reacted primarily with two DPB eplets and an allelic pair of DPA eplets. These data demonstrate that HLA class II reactive sera display distinct specificity patterns associated with structurally defined epitopes on different HLA-D alleles.
authors.affiliation: Division of Transplantation Pathology and Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15261, USA. Duquesnoyr@upmc.edu
authors.forename: Rene J
authors.initials: RJ
authors.lastname: Duquesnoy
authors.forename: Yehia
authors.initials: Y
authors.lastname: Awadalla
authors.forename: Jon
authors.initials: J
authors.lastname: Lomago
authors.forename: Larry
authors.initials: L
authors.lastname: Jelinek
authors.forename: Judy
authors.initials: J
authors.lastname: Howe
authors.forename: Dwayne
authors.initials: D
authors.lastname: Zern
authors.forename: Betty
authors.initials: B
authors.lastname: Hunter
authors.forename: Joan
authors.initials: J
authors.lastname: Martell
authors.forename: Alin
authors.initials: A
authors.lastname: Girnita
authors.forename: Adriana
authors.initials: A
authors.lastname: Zeevi
mesh_terms: D000906:Antibodies / Q000097:blood*; D000918:Antibody Specificity; D016022:Case-Control Studies; D000939:Epitopes / Q000737:chemistry / Q000276:immunology*; D006681:HLA-D Antigens / Q000737:chemistry / Q000276:immunology*; D006682:HLA-DP Antigens / Q000737:chemistry / Q000276:immunology; D006683:HLA-DQ Antigens / Q000737:chemistry / Q000276:immunology; D006684:HLA-DR Antigens / Q000737:chemistry / Q000276:immunology; D006650:Histocompatibility Testing; D006801:Humans; D019233:Retreatment; D014019:Tissue Donors; D014180:Transplantation
chemical_list: D000906:Antibodies; D000939:Epitopes; D006681:HLA-D Antigens; D006682:HLA-DP Antigens; D006683:HLA-DQ Antigens; D006684:HLA-DR Antigens